(Q34515565)

2 August 2017

1 reference

title

New concepts in the drug therapy of Alzheimer's disease (English)

1 reference

2 August 2017

0 references

Hake AM

1

1 reference

PubMed ID

11825329

2 August 2017

Farlow MR

series ordinal

2

1 reference

PubMed ID

11825329

2 August 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

Expert Opinion on Pharmacotherapy

2 August 2017

1 reference

2 August 2017

2

1 reference

2 August 2017

12

1 reference

2 August 2017

1975-1983

1 reference

Selective loss of central cholinergic neurons in Alzheimer's disease

2 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1975

Evolution of Alzheimer's disease-related cytoskeletal changes in the basal nucleus of Meynert.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1975

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1975

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1975

Venlafaxine: a novel antidepressant that has a dual mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1975

Neuroleptic sensitivity in patients with senile dementia of Lewy body type

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1975

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1975

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1975

The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1975

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1975

Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1975

Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1975

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1975

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1975

Oestrogens and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1975

Inflammation and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1975

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1975

Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1975

Somatic gene transfer to the adult primate central nervous system: in vitro and in vivo characterization of cells genetically modified to secrete nerve growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1975

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.12.1975

10.1517/14656566.2.12.1975

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11825329